在黑人患者中降低血压的Aprocitentan
John M Flack1, Markus P Schlaich2, Michael A Weber3
1Division of General Internal Medicine, Hypertension Section, Departments of Medicine and Population Science and Policy, Hypertension Section, Southern Illinois University School of Medicine, Springfield, IL (J.M.F.).
Hypertension (Dallas, Tex. : 1979)
|January 22, 2025
概括
阿普罗西坦有效降低了黑人抗高血压患者的血压 (BP) 和白蛋白尿. 这种双重内甲素受体抗剂在治疗难以控制的高血压方面显示出有前途.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 黑人患有更高的抗性高血压和心血管风险.
- 抗性高血压在管理心血管健康方面构成了重大挑战.
- 双内甲素受体抗剂正在研究它们的治疗潜力.
研究的目的:
- 为了评估阿普罗西坦在具有抗性高血压的黑人个体中降低血压 (BP) 的效果.
- 评估阿普罗西坦在特定的人口群体中的疗效和安全性.
- 在PRECISION研究群体中,将阿布罗西坦的效果与安慰剂进行比较.
主要方法:
- 这项研究招募了82名来自PRECISION试验的黑人个人.
- 参与者接受了阿普罗西坦坦 (12.5毫克或25毫克) 或安慰剂4周,随后延长治疗和重新随机化.
- 使用办公室和24小时门诊测量监测血压;还评估了白膜尿和不良事件.
主要成果:
- 阿普罗西坦显著降低了缩血压,特别明显的是24小时的门诊监测.
- 观察到办公室BP降低,在延长治疗和维护后再随机化期间持续影响.
- 阿普罗西坦显著减少了白蛋白尿,并指出外周胀是最常见的不良事件.
结论:
- 阿普罗西坦有效地降低了患有抗性高血压的黑人个体的血压和白蛋白尿.
- 药物的有效性在这个人群中反映了在更广泛的PRECISION研究队列中观察到的效果.
- 阿普罗西坦可以提供一种有价值的治疗选择,用于管理黑人患者的耐药高血压.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
576
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
576
01:25Antihypertensive Drugs: Direct Renin Inhibitors
480
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
480
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
463
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
463
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
01:27Open Angle Glaucoma: Treatment
389
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
389